|
Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. |
|
|
Stock and Other Ownership Interests - Conatus; Immunogen; Immunomedics; Novocure; Viking Medical |
Honoraria - Agendia; AstraZeneca; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer |
Consulting or Advisory Role - Agendia; Genentech; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology |
Speakers' Bureau - Agendia; Genentech; Genomic Health; Lilly; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Genentech; Lilly; Novartis; Pfizer |
|
|
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Amgen; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; bioTheranostics; Celgene; Eisai; Genentech; Lilly; Novartis; Pfizer; Puma Biotechnology; Sandoz |
Research Funding - Genentech (Inst) |
Travel, Accommodations, Expenses - Amgen; bioTheranostics; Celgene; Genentech/Roche; Pfizer |
|
|
Research Funding - Abbvie (Inst); H3 Biomedicine (Inst); Innocrin Pharma (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Daiichi Sankyo |
Research Funding - Amgen (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
Consulting or Advisory Role - Biotheranostics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo/Lilly (Inst); Eisai (Inst); Genentech/Roche (Inst); NanoString Technologies (Inst); Novartis (Inst) |
Speakers' Bureau - Genentech/Roche; Genentech/Roche; Novartis |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); InventisBio (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Novartis |
|
|
|
Stock and Other Ownership Interests - pfizer |
|
|
|
Stock and Other Ownership Interests - pfizer |
|
|
Employment - Corcept Therapeutics; Medivation; Pfizer |
Stock and Other Ownership Interests - Medivation; Pfizer |
Travel, Accommodations, Expenses - Medivation; Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Merrimack |
Patents, Royalties, Other Intellectual Property - Various patents through employment at Merrimack. |
|
|
Consulting or Advisory Role - AstraZeneca; Medivation/Pfizer; Pfizer |
Speakers' Bureau - Med Learning Group; Medscape; Physicans' Education Resource; UpToDate |
Research Funding - Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Jounce Therapeutics (Inst); Medivation/Pfizer (Inst); Novartis (Inst); pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - UptoDate |
Travel, Accommodations, Expenses - Med Learning Group; Medscape; Physicans' Education Resource |
|
|
Research Funding - Ambryx (Inst); Amgen (Inst); Bayer (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Dignitana (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); Medivation (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); sanofi (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Lilly; Novartis; OBI Pharma |